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Summary
Objective: An apparent database error in the sequence underlying the Helix-II cartilage biomarker immunoassay was investigated at the pro-
tein level.
Methods and results: Tandem mass spectrometry established the peptide sequence ERGETGPP*GPA in human type II collagen, not
ERGETGPP*GTS used to generate the antibody for the Helix-II assay.
Conclusions: Recent reports in which the Helix-II assay was applied to urine or serum as a marker of cartilage collagen degradation
need to be re-evaluated since the epitope does not occur in cartilage type II collagen. Based on collagen sequences and Helix-II epitope
properties, type III collagen is one of several candidate sources of the cross-reacting signal in body ﬂuids, but not type II collagen. The
ﬁndings highlight the need for more stringent scrutiny of the origins and validation of molecular markers in body ﬂuid assays in general.
ª 2009 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
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There is a pressing need to develop reliable biochemical
markers that can inform on the process of joint destruction
in osteoarthritis (OA), a disorder of essentially silent onset1.
Such markers could aid in drug development by identifying
fast progressors and detecting early response to therapy
and so reducing patient numbers and time required for clin-
ical trials. The NIH-sponsored Osteoarthritis Initiative (web
link: http://www.oai.ucsf.edu/) is a nationwide research
study and clinical sample resource that recognizes the
need to promote biomarker development. Body ﬂuid
markers of cartilage metabolism have received much re-
search attention, in particular type II collagen breakdown
products2. Since type II collagen is largely restricted to hy-
aline cartilages it presents an attractive target as a potential
monitor of joint erosion processes. Besides face validity,
however, it would seem wise to establish any candidate
marker by unequivocal molecular identiﬁcation in biological
samples as a prelude to wide-ranging, potentially mislead-
ing clinical applications. It is notable that of the several col-
lagen type II peptide-based immunoassays in clinical
research, none have been validated by deﬁnitive direct
methods as the primary signal generator in adult serum or
urine. These include CTX-II, TIINE and Helix-II as intended
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423With this in mind in reviewing the status of collagen II bio-
markers actively promoted through publications in the clini-
cal research literature, we noticed a curious anomaly in the
origin of the marker Helix-II originally described by Charni
et al.4. The authors reported selecting this target peptide im-
munogen by database searching for a unique occurrence in
the a1(II) chain among the different collagen gene products.
On inspection of DNA and Protein databases maintained by
NCBI (http://www.ncbi.nlm.nihgov/) however, it is apparent
that the target peptide sequence may owe its uniqueness
to a sequencing error in the original 1989 submission to
the Swiss Protein database (P02458)5. The genomic entry
for the Helix-II epitope sequence in COL2A1 encodes
ERGETGPPGPA not ERGETGPPGTS, the latter being
the basis of the immunogen for the Helix-II assay. To con-
ﬁrm beyond any doubt the nature of this collagen domain
at the protein level, we isolated the appropriate fragment
from human cartilage type II collagen and established its
structure directly by mass spectrometry.
A growing number of reports based on the Helix-II as-
say have appeared in the clinical research literature with
results interpreted in terms of its usefulness as a monitor
of joint cartilage degradation4,6e8. Here we conﬁrm at the
protein level that the Helix-II epitope is based on a non-
existent sequence and predict that a competing epitope,
possibly from type III collagen, is responsible for the clin-
ical ﬁndings.Methods
Consensus protein sequences were taken from the NCBI database us-
ing human genomic sequences for COL1A1, COL1A2, COL2A1 and
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for the Helix-II immunogen4. Collagen type II CNBr-derived fragments
were prepared from multiple samples of fetal human cartilage and adult
human articular cartilage. The fragment a1(II)CB10 containing the putative
Helix-II sequence was resolved from individual samples by SDS-PAGE, lo-
cated by Coomassie Blue staining, excised and digested in-gel with tryp-
sin9 prior to protein mass spectrometry. Resulting peptides were
subjected to microbore column liquid chromatography (Vydac C8 mass
spectrometry 0.3 mm 15 cm) interfaced directly to an ion trap tandem
mass spectrometer (Thermo Finnigan LCQ Deca XP) equipped with a mi-
cro-electrospray ionization source. Peptide sequences were identiﬁed by
comparison with the NCBI non-redundant protein database using Se-
quest, an automated database search algorithm designed for use with
tandem mass spectrometry data, and by manual interpretation of the
MS/MS fragmentation results.Results and discussion
Figure 1 compares homologous protein sequences from
the Human Genome database at NCBI for a1(II), a1(I)
and a1(III) collagen chains with that of the Helix-II sequence
as submitted in the original SwissProt Accession No.
P02458. As shown, a cDNA sequencing error in the original
submission and report5 misidentiﬁed TSGI in place of the
sequence PAGF, as subsequently established by the hu-
man genomic sequence. This error was corrected in later
P02458 database entries and in other COL2A1 cDNA sub-
missions but apparently overlooked in Helix-II assay
design4.
To be completely certain that this was wholly an artifac-
tual error of cDNA sequencing, and not for example the
result of a natural polymorphism, we screened more
than 10 individual collagen type II protein samples from
our bank of control fetal and adult human tissues. The
same tryptic peptide was recovered and identiﬁed by
mass spectrometry from them all. Its sequence is shown
in Fig. 2. The peptide mass and MS/MS fragmentation
data showed that PAGF not TSGI is the correct protein se-
quence at the Helix-II locus. We could not ﬁnd a TSGI ver-
sion in any sample examined.
What then is the source of the signal given by urine
and serum in the Helix-II immunoassay? Clearly human
urine and serum give an inhibitory signal and statistically
signiﬁcant differences are evident between patients and
control subjects in several clinical studies4,6e8. The He-
lix-II epitope can also be generated from human carti-
lage in vitro by cathepsin digestion10, shows diurnal
variability in urinary excretion11 and no response to es-
trogen in post-menopausal women or experimental
rats12.
The simplest explanation would be cross-reaction of the
antiserum raised against ERGETGPP*GTS, with peptidescDNA
error
correct
genomic
sequences
α 1 ( I I )
α 1 ( I I )
α 1 ( I )
α 1 ( I I I )
Fig. 1. Comparison of the Helix-II target epitope sequence (based
on original Swiss Protein uncorrected entry Accession No.
P02458) to homologous protein sequences at position 623e633
of the a1(II) helix from the human genome database for collagen
chains a1(II), a1(I) and a1(III).of the correct collagen type II peptide sequence, ER-
GETGPP*GPA, from this locus in the triple-helix. How-
ever, the control experiments of Charni et al. ruled this
out4. They synthesized the appropriate homologous pep-
tides for a1(I) and a1(III) chains, which showed no
cross-reactivity in the Helix-II inhibition assay. The
a1(III) sequence, ERGETGPP*GPA, is identical to that
of a1(II), so neither a1(II), a1(I) nor a1(III) can be the
source of the inhibition at least from peptides originating
at this helical locus. Rat type II collagen has the same
sequence, ERGETGPPGPA, as human, so the Helix-II
assay results reported for experimental rats12 have a sim-
ilar problem.
In their original assay validation, Charni et al.4 used
various synthetic peptides to establish the requirement
of a free C-terminal GTS sequence and hence proteolytic
neoepitope recognition. In addition, hydroxyproline at the
P* site of GPP*GTS gave a >10-fold higher afﬁnity than
proline. The helical domains of human a1(I), a2(I) and
a1(II) lack a GTS triplet, but the human a1(III) chain con-
tains two, one of which is in the context GPP*GTS (at res
16e21 of the a1(III) triple-helical domain) as in the a1(II)
artifactual sequence. One possibility, therefore, is that the
Helix-II immunoassay is measuring collagen type III
breakdown products in body ﬂuids. If so, it is not unrea-
sonable that in cross-sectional clinical studies comparing
patients and control subjects, signiﬁcantly elevated levels
of Helix-II signal will be found in keeping with observa-
tions using other generalized inﬂammatory markers (e.g.,
serum C-reactive protein and hyaluronic acid) in OA and
RA. Collagen type III turnover in the body is high and in-
deed as assessed by the serum type III N-propeptide as-
say, PIIINP, signiﬁcantly higher levels have been reported
for knee OA patients13. Etanercept, an anti-inﬂammatory,
is also likely to suppress type III collagen turnover14,
which would explain Helix-II ﬁndings with spondyloarthr-
opathy patients8. Adult human articular cartilage contains
signiﬁcant amounts of type III collagen15 which could ex-
plain the in vitro ﬁndings10. The GPPGTS motif is also
present in human a2(XI) and a5(IV) collagen (http://
www.ncbi.nlm.nih.gov/) so various alternative origins are
possible provided that proteolysis occurs after GTS.
Whatever the origin of the competing antigen(s), however,
it seems unlikely that the differences observed in clinical
studies are due primarily to metabolic processes in carti-
lage or even joint tissues.
There are important lessons from this cautionary tale.
The ﬁrst is the obvious need for care and oversight
when translating basic science into clinical application.
The second is the valuable insight from the clinical stud-
ies on the dangers of cross-reactivity when antibodies
raised against short collagen sequences are applied di-
rectly to biological ﬂuids. Signiﬁcant clinical differences
can be misleading. In short, the pitfalls are clear for all
biomarker validations that rely on ﬁndings from peptide-
based immunoassays in the absence of rigorous scien-
tiﬁc evidence that the intended peptide targets indeed
are responsible for the assay signal. Even when the au-
thentic peptide sequence is used for antibody production,
the only convincing and reliable proof would be to immu-
nopurify the binding partner(s) from the body ﬂuid using
the assay antibody and identify the peptide(s) and hence
their molecular origin by deﬁnitive methods, ideally mass
spectrometry. Finally, the important message is that the
scientiﬁc bar needs to be raised in the development
and validation of molecular markers in general for OA
research.
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Fig. 2. Direct conﬁrmation by tandem mass spectrometry that the a1(II) collagen sequence from human cartilage at helix residues 631e636 is
PAGF not TSGI. The upper panel shows the tryptic peptide proﬁle by total ion current (TIC) on HPLC from CNBr-fragment a1(II)CB10. The
middle panel shows the mass spectrum from the peptide encompassing the Helix-II epitope of mass that ﬁts the internal sequence PAGF
(not TSGI) and the lower panel the MS/MS fragmentation spectrum of the 12675þ ion conﬁrming the structure shown.
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